Jacob Steven Leach Sells 14,076 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jacob Steven Leach also recently made the following trade(s):

• On Wednesday, January 29th, Jacob Steven Leach sold 2,634 shares of DexCom stock. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94.

DexCom Trading Up 3.2 %

DXCM opened at $70.69 on Friday. The business’s 50-day simple moving average is $83.99 and its 200-day simple moving average is $76.89. The company has a market cap of $27.62 billion, a P/E ratio of 49.43, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently made changes to their positions in the company. PKO Investment Management Joint Stock Co acquired a new stake in shares of DexCom in the 4th quarter valued at about $3,733,000. Mattson Financial Services LLC lifted its stake in DexCom by 20.4% in the fourth quarter. Mattson Financial Services LLC now owns 21,119 shares of the medical device company’s stock valued at $1,642,000 after buying an additional 3,584 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $41,295,000. Capital A Wealth Management LLC purchased a new position in shares of DexCom during the fourth quarter worth approximately $203,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.